Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib ( HY-15772 ) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > TAM Receptor | Products > Signaling Pathways > Trk Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.